Revasc

RSS

Withdrawn

This medicine's authorisation has been withdrawn

desirudin
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 9 July 1997, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Revasc, which had been approved for prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery. The marketing authorisation holder (MAH) responsible for Revasc was Canyon Pharmaceuticals Limited. 

On 18 July 2014, the European Commission issued a decision to withdraw the marketing authorisation for Revasc, following its receipt of a letter dated 19 June 2014 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reason. Revasc was not marketed in any European country. 

Pursuant to this decision, the European public assessment report for Revasc is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (190.38 KB - PDF)

Ara

español (ES) (40.88 KB - PDF)

Ara

čeština (CS) (179.38 KB - PDF)

Ara

dansk (DA) (40.28 KB - PDF)

Ara

Deutsch (DE) (41.35 KB - PDF)

Ara

eesti (ET) (40.16 KB - PDF)

Ara

ελληνικά (EL) (184.52 KB - PDF)

Ara

français (FR) (41.26 KB - PDF)

Ara

italiano (IT) (41.21 KB - PDF)

Ara

latviešu (LV) (181.03 KB - PDF)

Ara

lietuvių (LT) (176.64 KB - PDF)

Ara

magyar (HU) (173.94 KB - PDF)

Ara

Malti (MT) (184.37 KB - PDF)

Ara

Nederlands (NL) (40.57 KB - PDF)

Ara

polski (PL) (188.74 KB - PDF)

Ara

português (PT) (41.33 KB - PDF)

Ara

română (RO) (171.2 KB - PDF)

Ara

slovenčina (SK) (176.83 KB - PDF)

Ara

slovenščina (SL) (168.36 KB - PDF)

Ara

suomi (FI) (40.31 KB - PDF)

Ara

svenska (SV) (40.46 KB - PDF)

Ara

Product information

български (BG) (696.71 KB - PDF)

Ara

español (ES) (334.91 KB - PDF)

Ara

čeština (CS) (558.2 KB - PDF)

Ara

dansk (DA) (337.62 KB - PDF)

Ara

Deutsch (DE) (343.51 KB - PDF)

Ara

eesti (ET) (331.91 KB - PDF)

Ara

ελληνικά (EL) (754.34 KB - PDF)

Ara

français (FR) (324.43 KB - PDF)

Ara

italiano (IT) (319.92 KB - PDF)

Ara

latviešu (LV) (589.48 KB - PDF)

Ara

lietuvių (LT) (417.62 KB - PDF)

Ara

magyar (HU) (566.96 KB - PDF)

Ara

Malti (MT) (650.42 KB - PDF)

Ara

Nederlands (NL) (353.06 KB - PDF)

Ara

polski (PL) (597.35 KB - PDF)

Ara

português (PT) (338.51 KB - PDF)

Ara

română (RO) (421 KB - PDF)

Ara

slovenčina (SK) (578.31 KB - PDF)

Ara

slovenščina (SL) (534.06 KB - PDF)

Ara

suomi (FI) (355.44 KB - PDF)

Ara

svenska (SV) (339.2 KB - PDF)

Ara

Íslenska (IS) (361.58 KB - PDF)

Ara

norsk (NO) (347.23 KB - PDF)

Ara
Latest procedure affecting product information:IAIN/0031/G
23/01/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (234.71 KB - PDF)

Ara

español (ES) (177.62 KB - PDF)

Ara

čeština (CS) (212.51 KB - PDF)

Ara

dansk (DA) (181.15 KB - PDF)

Ara

Deutsch (DE) (186.17 KB - PDF)

Ara

eesti (ET) (177.99 KB - PDF)

Ara

ελληνικά (EL) (212.16 KB - PDF)

Ara

français (FR) (179.52 KB - PDF)

Ara

italiano (IT) (176.79 KB - PDF)

Ara

latviešu (LV) (210.01 KB - PDF)

Ara

lietuvių (LT) (199.46 KB - PDF)

Ara

magyar (HU) (197.43 KB - PDF)

Ara

Malti (MT) (229.11 KB - PDF)

Ara

Nederlands (NL) (179.78 KB - PDF)

Ara

polski (PL) (210.74 KB - PDF)

Ara

português (PT) (179.96 KB - PDF)

Ara

română (RO) (220.16 KB - PDF)

Ara

slovenčina (SK) (208.39 KB - PDF)

Ara

slovenščina (SL) (183.94 KB - PDF)

Ara

suomi (FI) (176.24 KB - PDF)

Ara

svenska (SV) (181.18 KB - PDF)

Ara

Product details

Name of medicine
Revasc
Active substance
desirudin
International non-proprietary name (INN) or common name
desirudin
Therapeutic area (MeSH)
Venous Thrombosis
Anatomical therapeutic chemical (ATC) code
B01AE01

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.

Authorisation details

EMA product number
EMEA/H/C/000104
Marketing authorisation holder
Canyon Pharmaceuticals Ltd.

Canyon Pharmaceuticals Limited
7th Floor
52-54 Gracechurch Street
London
EC3V 0EH
United Kingdom

Marketing authorisation issued
09/07/1997
Withdrawal of marketing authorisation
18/07/2014
Revision
12

Assessment history

This page was last updated on

Share this page